Non-interventional Report on Parameters of Acceptability, Efficacy and Compliance of Fulvestrant in Post-menopausal Patients With Advanced Breast Cancer HR Positive Who Progresses to One Prior Endocrine Therapy With Antiestrogens
In Argentina, Faslodex is indicated for treating postmenopausal women with hormone
receptor-positive locally advanced or metastatic breast cancer with recurrence during or
after adjuvant anti-oestrogen therapy or disease progression during anti-oestrogen
treatment. This study will provide information regarding the acceptability and compliance of
Argentina patients to Faslodex and will provide information regarding the efficacy of this
treatment in local population.
Observational Model: Cohort, Time Perspective: Prospective
To collect real life data of acceptability and compliance on the use of Faslodex in the Argentine population.
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica